2m 2m 2m 2m 2m 2m 2m
ELICIO THERAPTCS (ELTX)
NASDAQ
$12.47-$0.06 (-0.48%)
Price as of Jun 03, 2026 4:31 PM EDT- $218.3MMarket Cap
- 54.69%1-Year Change
- BiotechnologyIndustry
ELICIO THERAPTCS (ELTX)
$12.47-$0.06 (-0.48%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | 2.3M -91.87% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | 0 -100.00% | |
Gross Profit | 0 N/A | 0 N/A | 0 -100.00% | 2.3M -91.75% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -24.9M -26.01% | -33.7M +41.12% | -23.8M +31.76% | -18.1M -62.83% | |
Depreciation and Amortization Expense | 204,000 -36.45% | 321,000 -15.97% | 382,000 +114.61% | 178,000 +95.60% | |
Total Operating Expenses | 37.7M -16.17% | 45.0M +25.85% | 35.7M -14.73% | 41.9M -38.00% | |
Operating Profit | -37.7M -16.17% | -45.0M +25.85% | -35.7M -9.78% | -39.6M +0.80% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -100,000 -50.00% | -200,000 -81.11% | -1.1M N/A | N/A N/A | |
Interest Income and Expense and Net | -100,000 -50.00% | -200,000 -81.11% | -1.1M N/A | 0 +100.00% | |
Total Nonoperating Income and Expense | -1.9M -73.13% | -6.9M -1,356.73% | 550,000 -32.43% | 814,000 +105.33% | |
Income before Taxes | -37.7M -16.17% | -45.0M +25.85% | -35.7M -9.78% | -39.6M +0.80% | |
Income Taxes | 0 N/A | 0 N/A | 0 -100.00% | 11,000 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -39.6M -23.75% | -51.9M +47.46% | -35.2M -9.31% | -38.8M -28.89% | |
Net Income from Continuing Operations Applicable to Common | -39.6M -23.75% | -51.9M +47.46% | -35.2M -9.31% | -38.8M -28.89% | |
Basic EPS and Net Income | -2.58 -39.29% | -4.25 -38.94% | -6.96 +439.53% | -1.29 -33.16% | |
Diluted EPS and Net Income | -2.58 -39.29% | -4.25 -38.94% | -6.96 +439.53% | -1.29 -33.16% | |
Basic Weighted Average Shares | 15.3M +25.48% | 12.2M +141.35% | 5.1M -83.17% | 30.0M +6.36% | |
Diluted Weighted Average Shares | 15.3M +25.48% | 12.2M +141.35% | 5.1M -83.17% | 30.0M +6.36% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 18.6M +5.36% | 17.6M +36.64% | 12.9M -74.46% | 50.5M -43.12% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 18.6M +5.36% | 17.6M +36.64% | 12.9M -74.46% | 50.5M -43.12% | |
Total Current Assets | 19.3M -6.68% | 20.7M +26.58% | 16.3M -68.21% | 51.4M -43.64% | |
Accumulated Depreciation | 1.8M +13.14% | 1.6M +26.08% | 1.2M +77.12% | 695,000 +34.43% | |
Property and Plant and Equipment and Net | 295,000 -38.92% | 483,000 -32.64% | 717,000 +162.64% | 273,000 -39.47% | |
Total Long-Term Assets | 295,000 -38.92% | 483,000 -32.64% | 717,000 +1,075.41% | 61,000 -42.45% | |
Total Assets | 25.9M -8.22% | 28.2M +3.80% | 27.1M -48.58% | 52.8M -45.30% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 0 N/A | |
Total Current Liabilities | 8.1M -29.62% | 11.5M +17.99% | 9.8M +53.34% | 6.4M -43.62% | |
Total Long-Term Debt | 9.4M -53.04% | 20.0M N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 16.1M +103.15% | 7.9M +32.06% | 6.0M +142.12% | 2.5M -28.60% | |
Total Liabilities | 24.2M -38.65% | 39.5M +150.36% | 15.8M +74.91% | 9.0M -39.90% | |
Retained Earnings | -233.7M +20.39% | -194.1M +36.50% | -142.2M -44.00% | -253.9M +18.04% | |
Total Stockholders Equity | 1.6M +114.46% | -11.3M -199.46% | 11.4M -74.02% | 43.8M -46.30% | |
Total Shares Outstanding | 17.8M +61.39% | 11.0M +14.84% | 9.6M -68.11% | 30.1M +0.52% | |
Cash Flow | |||||
Cash from Operating Activities | -37.0M -0.31% | -37.1M +13.38% | -32.7M -14.84% | -38.4M -27.07% | |
Capital Expenditures | 16,000 -81.61% | 87,000 +31.82% | 66,000 N/A | 0 -100.00% | |
Cash from Investing Activities | -16,000 -80.95% | -84,000 +162.50% | -32,000 N/A | 0 +100.00% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 36.7M -13.29% | 42.3M +9.60% | 38.6M +64,455.00% | -60,000 -100.06% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | 100.00% N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | -1,721.90% N/A | |
Return on Assets | -146.45% -21.94% | -187.61% +113.06% | -88.06% +69.39% | -51.98% N/A | |
Return on Equity | 817.92% +100.48% | -170,157.38% +133,204.85% | -127.65% +106.04% | -61.95% N/A | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | -91.87% N/A | |
Current Ratio | 2.38 +32.59% | 1.80 +7.28% | 1.67 -79.27% | 8.08 N/A | |
Cash Ratio | 2.29 +49.71% | 1.53 +15.80% | 1.32 -83.34% | 7.93 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow